Financial Perspectives’s Sarepta Therapeutics SRPT Stock Holding History

Financial Perspectives’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.3K	Hold	128	–	–	﹤0.01%	645
2026 Q1	$2.79K	Hold	128	–	–	﹤0.01%	627
2025 Q4	$2.75K	Hold	128	–	–	﹤0.01%	624
2025 Q3	$2.47K	Hold	128	–	–	﹤0.01%	625
2025 Q2	$2.19K	Hold	128	–	–	﹤0.01%	626
2025 Q1	$8.17K	Hold	128	–	–	﹤0.01%	524
2024 Q4	$15.6K	Hold	128	–	–	0.01%	450
2024 Q3	$16K	Hold	128	–	–	0.01%	417
2024 Q2	$20.2K	Hold	128	–	–	0.01%	380
2024 Q1	$16.6K	Hold	128	–	–	0.01%	398
2023 Q4	$12.3K	Hold	128	–	–	0.01%	448
2023 Q3	$15.5K	Hold	128	–	–	0.01%	388
2023 Q2	$14.7K	Hold	128	–	–	0.01%	405
2023 Q1	$17.6K	Hold	128	–	–	0.01%	375
2022 Q4	$16.6K	Hold	128	–	–	0.01%	383
2022 Q3	$14.1K	Hold	128	–	–	0.01%	396
2022 Q2	$9.6K	Hold	128	–	–	0.01%	445
2022 Q1	$10K	Hold	128	–	–	﹤0.01%	462
2021 Q4	$11.5K	Hold	128	–	–	0.01%	429
2021 Q3	$11.8K	Hold	128	–	–	0.01%	424
2021 Q2	$9.95K	Buy	+128	New	+$9.7K	﹤0.01%	462

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Financial Perspectives's SRPT Position: Q2 2026 in Review

Financial Perspectives held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 128 shares worth $2.3K. The position accounts for ﹤0.01% of the portfolio, ranked #645.

Financial Perspectives first reported a position in SRPT in Q2 2021 and has held it in 21 quarters since. The position peaked at $20.2K in Q2 2024. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Financial Perspectives held 128 shares of Sarepta Therapeutics worth $2.3K as of Q2 2026.
Financial Perspectives left its Sarepta Therapeutics share count unchanged in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of Financial Perspectives's portfolio in Q2 2026, its #645 holding.
Financial Perspectives first reported a position in Sarepta Therapeutics in Q2 2021 and has held it in 21 quarters since.
Financial Perspectives's Sarepta Therapeutics position peaked at $20.2K in Q2 2024.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Financial Perspectives's 13F filing for Q2 2026, filed 24 Jul 2026.